Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with Chidamide and Azacitidine for ENKTL-HLH
NCT05008666Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Extranodal NK/T-cell lymphoma (ENKTL), hemophagocytic lymphohistiocytosis (HLH), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05008666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008666.